|
Laxman Pai, Opalesque Asia: Cowen Healthcare Investments (CHI) has raised $493m for its third flagship investment vehicle, beating its initial $400m target.
The private healthcare investment strategy within the investment management division of Cowen Inc said in a press release that it received commitments from existing and new investors, including institutional investors, family offices, and high net worth individuals.
The fund closure positions Cowen to continue following an investment strategy that has seen it invest in biotechs such as Akouos, AM-Pharma, and Keros Therapeutics in recent months.
Over the past eight years, Cowen has backed 38 private healthcare companies from its two previous funds. While the funds invest across biopharma, diagnostics, and digital health, drug developers have been a significant area of focus for the Cowen investment team led by Kevin Raidy, Tim Anderson and Robert Sine.
Led by Kevin Raidy, Tim Anderson, and Robert Sine, CHI was founded in 2012 to support innovation in the healthcare sector, with a particular focus on biopharma, diagnostics and digital health.
Kevin Raidy, Managing Partner, CHI, said, "Investing in premier life sciences companies could not be more critical than it is today. We are extremely optimistic about the prospects of this industry to address urgent, unmet medical needs, and in doing so to transform the lives of patients and their families. We feel privileged to be able to partner with exceptional ma...................... To view our full article Click here
|
RSS
